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Abstract
Background: High mobility group box 1 protein (HMGB1) plays an important role in myo­
cardial ischemia and reperfusion (I/R) injury. Exendin­4 (Ex­4), glucagon­like peptide­1 
receptor agonist, has been reported to attenuate myocardial I/R injury. This study was to 
investigate the potential mechanism by which Ex­4 attenuates myocardial I/R injury in rats.
Methods: Anesthetized male rats were once treated with Ex­4 (5 µg/kg, i.v.) 1 h before ische­
mia in the absence and/or presence of exendin(9­39) (an antagonist for glucagon­like peptide­1 
receptor, 5 µg/kg, i.v.), and then subjected to ischemia for 30 min followed by reperfusion for 4 h.  
Lactate dehydrogenase (LDH), creatine kinase (CK), malondialdehyde (MDA), superoxide 
dismutase (SOD) activity and infarct size were measured. HMGB1 expression was assessed 
by immunoblotting.
Results: The results showed that pretreatment of Ex-4 could significantly decrease the infarct 
size and the levels of LDH and CK after 4 h reperfusion (all p < 0.05). Ex-4 could also signifi­
cantly inhibit the increase of the MDA level, the decrease of the SOD level (both p < 0.05). Mean ­ 
while, Ex-4 could significantly inhibit HMGB1 expression induced by I/R. Administration of 
exendin(9­39) could abolish the protective effect of Ex­4 (all p < 0.05). 
Conclusions: The present study suggested that Ex­4 could attenuate myocardial I/R injury 
which may be associated with inhibiting HMGB1 expression. (Cardiol J 2013; 20, 6: 600–604)
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Introduction
High mobility group box 1 protein (HMGB1), 
a non-chromosomal nuclear protein that regulates 
gene transcription and maintains the nucleosome 
structure, could be negatively released by necrotic 
cell, apoptotic cell or positively activated innate im-
mune cells (such as macrophages and monocytes) 
[1, 2]. HMGB1 has been identified as a novel pro-
-inflammatory cytokine in several cardiovascular 
diseases [3–6]. Recently, HMGB1 has been found 
to function as an early pro-inflammatory mediator 
during myocardial ischemia and reperfusion (I/R), 
as well as some classical early pro-inflammatory 
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cytokine such as tumor necrosis factor-a (TNF-a), 
interleukin-6 (IL-6) and could promote the release 
of TNF-a and IL-6, whereas HMGB1 A box peptide 
(a specific HMGB1 antagonist) could protect aga-
inst myocardial I/R injury and inhibit the release of 
TNF-a and IL-6 [3], while inflammatory response is 
considered to be a critical factor of myocardial I/R 
injury [7, 8]. These results suggested that HMGB1 
plays an important role in myocardial I/R injury.
Glucagon-like peptide-1 (GLP-1), a gut incretin 
hormone secreted from L cells in the intestine in 
response to food intake, has been considered an at-
tractive agent for the management of type-2 diabetes 
mellitus [9]. The GLP-1 receptor agonist-exendin-4 
(Ex-4), a 39 amino acid peptide, has been shown to 
activate GLP-1 receptors to increase intracellular 
cAMP in pancreatic acinar cells and has no effect 
on VIP receptors, functioning identically to GLP-1. 
A growing body of evidence shows that GLP-1 and Ex-4 
could provide significant beneficial effects for cardio-
vascular diseases, including myocardial I/R, in both 
experimental animal models and patients [10–13]. 
Recently, Cai et al. [14] have found that Ex-4 could 
inhibit HMGB1 expression induced by high glucose 
condition in cardiomyocytes. Thus, the hypothesis 
that Ex-4 may attenuate myocardial I/R injury by 
inhibiting HMGB1 expression was tested in a rat 
myocardial I/R model in the present study.
Methods
Animal preparation and experimental designs
The experiment protocol conformed to the 
Guide for the Care and Use of Laboratory Ani-
mals published by the US National Institutes of 
Health (NIH Publication, revised in 1996) and was 
approved by the Institutional Animal Care and Use 
Committee. Male Sprague-Dawley rats (250–300 g) 
were randomly assigned into 4 groups receiving 
the following treatments: 
—  Group 1: sham operated control (SO) (n = 10): 
rats were subjected to surgical manipulation 
without the induction of myocardial ischemia; 
—  Group 2: ischemia and reperfusion (I/R) (n = 
= 15): rats were subjected to the left anterior 
descending coronary artery (LAD) occlusion 
for 30 min followed by reperfusion for 4 h; 
—  Group 3: Ex-4 + I/R (Ex-4 – I/R) (n = 15): 
the rats were once treated with Ex-4 (5 µg/
kg, i.v., Sigma, USA) [15, 16] 1 h before LAD 
occlusion, and subjected to LAD occlusion for 
30 min and followed by reperfusion for 4 h. 
Ex-4 was dissolved in sterile saline; 
—  Group 4: Ex-4 + exendin(9-39) [Ex(9-39)]+I/R 
(Ex-4-I/R) (n = 15) the rats were once trea-
ted with Ex-4 (5 µg/kg, i.v.) and Ex(9-39) (an 
antagonist for GLP-1 receptor, 5 µg/kg, i.v., 
Sigma, USA) [12] 1 h before LAD occlusion, 
and subjected to LAD occlusion for 30 min and 
followed by reperfusion for 4 h. Ex(9-39) was 
dissolved in sterile saline.
After being anesthetized with sodium pento-
barbital (45 mg/kg, i.p.), the rats were ventilated 
artificially with a volume-controlled rodent respi-
rator at 70 strokes per minute. Rats were placed 
on an electric heating pad to maintain the body 
temperature at 37°C. Heparin (200 IU/kg, i.v.) was 
given before ischemia. Lead-II of the electrocardio-
gram was monitored with subcutaneous stainless 
steel electrodes. Electrocardiogram was monitored 
using a computer-based EP system (LEAD2000B, 
Jinjiang Ltd, China). 
A thoracotomy through a left parasternal in-
cision was performed to expose the anterior wall 
of the left ventricle. A 4–0 silk suture on a small 
curved needle was passed through the myocardium 
beneath the middle segment of the LAD branch 
coursing down the middle of the anterior wall of 
the left ventricle. A small vinyl flake was passed 
into both ends of the suture, which was then fixed 
by champing the tube with a mosquito hemostat. 
A successful myocardial I/R model was confirmed 
by ST segment elevation in leads-II and regional 
cyanosis of the myocardial surface. The rats subje-
cted to a 30-min occlusion of the LAD and followed 
by a 4 h reperfusion. 
Assessment of myocardial injury
To assess the lactate dehydrogenase (LDH) 
and creatine kinase (CK), blood samples were col-
lected and centrifuged. Standard techniques using 
commercialized assay kits in accordance with the 
manufacturer’s instructions (Nanjing Jiancheng 
Bioengineering Institute, China) were used for the 
analyses. Values were expressed in international 
units per liter.
Assessment of the infarct size 
The infarct size was established by 2,3,5-tri-
phenyltetrazolium chloride (TTC, Sigma-Aldrich) 
staining as described previously [17]. Briefly, after 
reperfusion the LAD was occluded again and 2 mL 
of 1.0% evans blue dye was injected via the femo-
ral vein. Each heart was then sliced horizontally 
to yield 5 slices. The slices were incubated in 1% 
TTC for 15 min at 37°C. The infarct area (white) 
and the area at risk (red and white) from each 
section were measured using an image analyzer 
(Image-Pro Plus 3.0, Media Cybernetics, Silver 
Spring, MD). The infarct size was expressed as 
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a percentage of the risk area volume (%, infarct 
size/risk area).
MDA and SOD activity assay
Measurement of myocardium malondialdehyde 
(MDA) concentration and superoxide dismutase 
(SOD) activity in myocardial tissue were measured 
using commercialized assay kits in accordance with 
the manufacturer’s instructions (Nanjing Jiancheng 
Bioengineering Institute, China), as described in 
the previous study [14]. The former were used as 
indexes of oxygen free radical and the latter as lipid 
superoxide level in the myocardium, respectively. 
Immunoblotting analysis
Pulverized frozen ischemia area of left ven-
tricle samples were analyzed by quantitative 
immunoblotting using HMGB1 antibody (Santa 
Cruz, USA) as described in the previous study 
[14]. The expression of protein was normalized 
to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) expression.
Statistical analysis
Statistical analysis was performed with the 
SPSS 16.0 (SPSS Inc., Chicago, IL, USA). All values 
were expressed as mean ± standard deviation. 
One-way ANOVA or Welch was used for compa-
risons among groups and the Least-significant 
Difference or Dunnett T3 was used for post­hoc 
multiple comparisons. Statistical significance was 
defined as p < 0.05.
Results
Infarct size
After 4 h reperfusion, the infarct size induced 
by I/R was decreased by Ex-4 pretreatment compa-
red with that in I/R group (p < 0.05). Administra-
tion of Ex(9-39) could abolish the protective effect 
of Ex-4 on infarct size (p < 0.05; Fig. 1).
LDH and CK levels
After 4 h reperfusion, both LDH and CK levels 
in I/R group were significantly increased compa-
red to that in SO group (p < 0.05). However, the 
increase of LDH and CK levels was significantly 
attenuated by Ex-4 (both p < 0.05). Administration 
of Ex(9-39) could abolish the protective effect of 
Ex-4 on myocardial enzyme (p < 0.05) (Fig. 2).
MDA and SOD levels
After 4 h reperfusion, the MDA level in I/R 
group was significantly increased while the SOD 
level was significantly decreased compared to 
that in SO group (p < 0.05). Both the increase 
of the MDA level and the decrease of the SOD 
level were significantly inhibited by Ex-4 (both 
p < 0.05). Administration of Ex(9-39) could abolish 
the protective effect of Ex-4 on oxidative stress 
(p < 0.05) (Fig. 3).
HMGB1 expression
As shown in Figure 4, HMGB1 expression was 
markedly increased after 4 h reperfusion (p < 0.05), 
which was significantly inhibited by Ex-4 (p < 0.05). 
Administration of Ex(9-39) could abolish the pro-
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Figure 1. Effect of Ex-4 on infarct size during I/R (n = 5); 
 p < 0.05 vs. I/R group;  p < 0.05 vs. Ex-4-I/R group; 
Ex-4 — exendin-4; I/R — ischemia and reperfusion; 
Ex(9-39) — exendin(9-39).
Figure 2. Effect of Ex-4 on LDH and CK during I/R (n = 10); 
#p < 0.05 vs. SO group;  p < 0.05 vs. I/R group; 
 p < 0.05 vs. Ex-4-I/R group; LDH — lactate dehydro-
genase; CK — creatine kinase; SO — sham operated 
control; other abbreviations are identical with those 
from Figure 1.
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Discussion
Previous studies showed that GLP-1 and GLP-1 
receptor agonists could attenuate myocardial 
I/R injury and improve cardiac function [10–12, 
18]. In this study, we found that GLP-1 receptor 
agonists-Ex-4 could attenuate myocardial I/R 
injury. Meanwhile, we observed that Ex-4 could 
inhibit HMGB1 expression induced by I/R. While 
using an antagonist for GLP-1 receptor abolish the 
protective effect of Ex-4 on myocardial I/R injury 
and HMGB1 expression. Hu et al. [19] demonstra-
ted that HMGB1 could promote the apoptosis of 
cardiomyocytes in a dose-dependent manner while 
apoptosis plays a critical role in myocardial I/R in-
jury accompanied by inflammation [7, 20]. HMGB1 
could promote the release of TNF-a, IL-6 during 
myocardial I/R, whereas a specific HMGB1 anta-
gonist could attenuate myocardial I/R injury and 
inhibit the release of TNF-a and IL-6 [3], indicating 
that inhibiting HMGB1 expression could suppress 
the inflammatory process and myocardial I/R in-
jury. Thus, the above results suggest that Ex-4 
could attenuate myocardial I/R injury which may 
be associated with inhibiting HMGB1 expression.
In addition, we found that pretreatment of Ex-4 
could decrease the level of MDA (one of reactive 
oxygen species and as index for oxidative stress) 
and increase the level of SOD (key antioxidant 
enzymes). Previous studies indicated that oxidative 
stress may be involved in the release of HMGB1. 
Tang et al. [21] reported that hydrogen peroxide, 
one of reactive oxygen species, could stimulate 
macrophages and monocytes to actively release 
HMGB1. Tsung et al. [22] further confirmed that 
HMGB1 released from cultured hepatocytes was 
also found to be an active process regulated by 
reactive oxygen species, indicating that inhibiting 
reactive oxygen species may decrease the HMGB1 



























































Figure 4. Effect of Ex-4 on HMGB1 expression during 
I/R (n = 5); #p < 0.05 vs. SO group;  p < 0.05 vs. I/R 
group;  p < 0.05 vs. Ex-4-I/R group; HMGB1 — high 
mobility group box 1 protein; GAPDH — glyceralde-
hyde-3-phosphate dehydrogenase; other abbreviations 
are identical with those from Figure 1 and Figure 2.
Figure 3. Effect of Ex-4 on MDA and SOD during I/R (n = 5); #p < 0.05 vs. SO group;  p < 0.05 vs. I/R group; 
  p < 0.05 vs Ex-4-I/R group; MDA — malondialdehyde; SOD — superoxide dismutase; other abbreviations are 
identical with those from Figure 1 and Figure 2.
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ment of Ex-4 could inhibit HMGB1 expression 
which may be associated with inhibiting reactive 
oxygen species induced by myocardial I/R.
Limitations of the study
In the study, we only investigated the effect 
of Ex-4 on myocardial I/R injury and HMGB1 ex-
pression. The precise mechanisms underlying our 
observation will require future elucidation.
Conclusions
The present study suggested that Ex-4 could 
attenuate myocardial I/R injury which may be as-
sociated with inhibiting HMGB1 expression.
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